Managing Severe Emphysema: Comparing Lung Volume Reduction Surgery and Bronchoscopic Procedures

For patients with severe emphysema, two primary interventions—Lung Volume Reduction Surgery (LVRS) and Bronchoscopic Lung Volume Reduction (BLVR)—aim to improve lung function by removing or bypassing non-functional, overinflated tissue. While LVRS remains a gold-standard surgical option for appropriately screened candidates, BLVR has emerged as a less invasive, non-surgical alternative that utilizes endobronchial valves to achieve similar clinical improvements in select patients.

What Is Lung Volume Reduction Surgery (LVRS)?

LVRS is a surgical procedure designed to remove the most damaged, hyperinflated portions of the lungs. By excising this non-functioning tissue, surgeons allow the remaining, healthier lung tissue to expand and function more efficiently, according to the National Heart, Lung, and Blood Institute (NHLBI). The procedure aims to improve breathing mechanics, exercise capacity, and overall quality of life for patients who suffer from severe chronic obstructive pulmonary disease (COPD).

Candidates for LVRS must undergo rigorous screening. The American Thoracic Society (ATS) emphasizes that successful outcomes depend heavily on identifying patients with heterogeneous emphysema—where disease is concentrated in specific areas—and those who have completed pulmonary rehabilitation. Because it involves general anesthesia and incisions, it carries the inherent risks of major surgery, including infection, respiratory failure, and prolonged hospital stays.

How Does Bronchoscopic Lung Volume Reduction (BLVR) Work?

BLVR is a minimally invasive procedure that achieves lung volume reduction without the need for surgical incisions. Physicians use a bronchoscope to place small, one-way valves into the airways leading to the most diseased parts of the lung, as described by the Mayo Clinic. These valves prevent air from entering the damaged lobes while allowing trapped air and secretions to escape, effectively deflating the hyperinflated tissue.

The primary advantage of BLVR is its reduced recovery time compared to open or thoracoscopic surgery. However, not all patients are eligible. The U.S. Food and Drug Administration (FDA) notes that patient selection is critical; candidates must be free of collateral ventilation—a condition where air can bypass the valves via connections between lung segments—to ensure the targeted lung lobe successfully deflates.

Clinical Comparison: Surgery vs. Bronchoscopy

What Are the Key Considerations for Patients?

Determining the appropriate therapy requires a multidisciplinary evaluation. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), clinical decision-making should be based on a combination of high-resolution computed tomography (CT) scans, pulmonary function testing, and exercise tolerance assessments.

Patients should discuss these factors with their pulmonologist:

• Collateral Ventilation: The presence of fissures between lung lobes may disqualify a patient from BLVR, making surgery the only viable option.
• Disease Distribution: Patients with diffuse disease may not see significant benefits from either procedure, as both treatments rely on targeting localized areas of hyperinflation.
• Comorbidity Profile: A patient’s overall cardiovascular health and ability to tolerate general anesthesia often dictate whether they are candidates for surgical intervention.

While BLVR has expanded the pool of patients eligible for lung volume reduction, it is not a replacement for medical management or pulmonary rehabilitation. Both surgical and bronchoscopic approaches are intended to be used alongside optimal pharmacological therapy, such as long-acting bronchodilators, to manage severe emphysema effectively.